Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics: Q2 Earnings Snapshot

08/04/2021 | 05:43pm EST

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Wednesday reported a loss of $30.8 million in its second quarter.

The Newark, California-based company said it had a loss of 69 cents per share.

The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share.

The biopharmaceutical company posted revenue of $2.3 million in the period.

Protagonist Therapeutics shares have more than doubled since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $48.98, more than tripling in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PTGX at https://www.zacks.com/ap/PTGX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about PROTAGONIST THERAPEUTICS, INC.
01/04/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
PR
2021INSIDER SELL : Protagonist Therapeutics
MT
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
CI
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
CI
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
2021Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
MT
2021JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps ..
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 23,8 M - -
Net income 2021 -127 M - -
Net cash 2021 248 M - -
P/E ratio 2021 -9,73x
Yield 2021 -
Capitalization 1 259 M 1 259 M -
EV / Sales 2021 42,4x
EV / Sales 2022 42,6x
Nbr of Employees 116
Free-Float 98,9%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 26,38 $
Average target price 59,00 $
Spread / Average Target 124%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-22.87%1 259
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892